Skip to main content
OncoLattice BioONCOLOGY ENROLLMENT INTELLIGENCE

01 / BEFORE SITE SELECTION / Site Selection & Feasibility Intelligence

Which sites should we open—and what can they realistically enroll?

Turn an existing protocol into a prioritized site plan. We combine patient opportunity, competition, investigator context and operating evidence to explain where the trial can work and what enrollment to expect.

Concept illustration: a world map with alternative development paths and timelines, not an operational footprint.

What you receive

A prioritized site plan

A recommended order, alternatives and the evidence behind each site's fit with the protocol.

Realistic enrollment expectations

Site-level ranges over an agreed period, with screening, timing, competition and capacity assumptions made explicit. Estimates are distinguished from observed performance.

Risks that could change the plan

Data gaps, historical performance where available, referral and testing constraints, and the site or PI confirmations that matter.

View the output example
Illustrative evidence desk with pathology imagery, molecular models, a timeline and a map; not patient data.

What you bring

  • Protocol and relevant eligibility criteria
  • Target regions, enrollment objective and planning window
  • An existing shortlist, if available, and sponsor or CRO context

You bring the trial context. We scope the evidence.

OncoLattice identifies the evidence needed and coordinates access through appropriately licensed, partner-supplied or sponsor-provided sources. Available coverage, procurement responsibility, cost and permitted uses are confirmed before work begins. Having a complete patient database is not a prerequisite for an initial discussion.

Agree the deliverables, data access, review responsibilities, timing, fees and acceptance criteria before work begins. This is a scoped service—not access to a self-serve patient database.

How the work moves forward

Sponsors retain site-selection decisions. Sites and execution partners confirm current capacity and operating readiness; those findings inform the recommendation and its assumptions.

ONCOLOGY ENROLLMENT INTELLIGENCE

Where is your trial today?

Tell us whether you are choosing sites or working with sites already selected. Start with non-confidential context; we will define the relevant deliverable and access arrangements together.

Discuss your trial